Transgene takes a hit as Novartis shreds $800M option deal

John Carroll

France's took a hit this morning after the biotech announced that had decided to pass on its for the therapeutic cancer vaccine TG4010. But the CEO says he's laying the groundwork for a late-stage study, confident that he can find another partner.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS